BETSHY

Tag: Public Health

  • Schizoid Guilt: The Hidden Emotional Prison Nobody Talks About

    Schizoid Guilt: The Hidden Emotional Prison Nobody Talks About

    Guilt is one of the most universally human of all emotional experiences. We are taught, from early childhood , that guilt is the natural and appropriate response to wrongdoing — a signal from the conscience that a social or moral boundary has been crossed. But not all guilt operates in this way, and not all guilt is what it appears to be. There is a form of guilt so deeply embedded in the architecture of certain personalities that it functions not as a moral compass but as a prison: inescapable, unresolvable, and largely invisible even to the person who carries it. This is schizoid guilt — one of the least discussed yet most clinically significant dimensions of the schizoid condition, rooted in some of the most important theoretical developments in twentieth-century psychoanalysis, and profoundly relevant to how we understand emotional suffering today (Get Therapy Birmingham, 2025 ).

    Advertisements

    What Is Schizoid Guilt?

    To understand schizoid guilt, it is necessary first to understand the schizoid condition itself. Schizoid Personality Disorder (SPD) is characterised by a pervasive pattern of detachment from social relationships, a restricted range of emotional expression in interpersonal settings, and a preference for solitary activity and inner life over engagement with the external world (Salters-Pedneault, 2024). Beneath this observable withdrawal, however, lies an inner world of far greater complexity and depth than the surface behaviour suggests — a world populated by intense emotional need, profound longing for connection, and, crucially, an enduring and painful relationship with guilt (ScienceDirect, 2024).

    Schizoid guilt is not the ordinary, object-directed guilt of someone who has acted wrongly toward another person and seeks to make amends. It is, rather, a more primitive, internalised, and largely unconscious form of self-torment — what the psychoanalytic tradition describes as the guilt of someone who has come to believe, at a deeply pre-verbal level, that they themselves are the cause of every relational failure they have experienced (Carveth, n.d.). It is a guilt that cannot easily be discharged through confession, repair, or remorse, because it is not primarily a response to a specific action. It is a response to being.

    The Theoretical Origins: Fairbairn and the Paranoid-Schizoid Position

    The conceptual roots of schizoid guilt lie primarily in the object relations theory of the Scottish psychoanalyst W.R.D. Fairbairn, whose revolutionary revisions to Freudian psychoanalysis in the 1940s and 1950s established the developmental and structural framework through which the schizoid personality is most coherently understood. Fairbairn proposed that the fundamental human motivation is not the discharge of instinctual tension, as Freud had argued, but the search for relationship — for a satisfying, loving connection with another person (Get Therapy Birmingham, 2025 ). When early caregiving environments fail to provide this — when the infant or young child encounters a parent who is emotionally unavailable, unpredictable, neglectful, or actively rejecting — the developmental consequences are profound and lasting.

    Melanie Klein, incorporating and extending Fairbairn’s insights, described the earliest phase of psychological life as the paranoid-schizoid position — a developmental state characterised by splitting, persecutory anxiety, and primitive defences. It is here, Klein argued, that the seeds of both schizoid and depressive psychopathology are sown (Christiansen, 2025). The schizoid individual, having been arrested at or returned to this early developmental position, remains caught in a relational world experienced through part-objects, splitting, and the constant terror of emotional annihilation.

    The Moral Defence: Guilt as a Protection Against Something Worse

    Fairbairn’s most clinically significant contribution to understanding schizoid guilt is his concept of the moral defence — the unconscious psychological manoeuvre by which a child who has experienced inadequate or absent parental love resolves an otherwise unbearable existential dilemma. The dilemma is this: if the parent who is supposed to love and protect me is bad, then the world is dangerous, and I am helpless. This conclusion is psychologically intolerable for a dependent child. The solution — arrived at unconsciously and automatically — is to relocate the badness from the parent to the self. It is not my parent who is bad; it is I who am bad, unlovable, defective. And if I am the cause of the relational failure, then perhaps by changing — by becoming good enough, small enough, invisible enough — I can restore the love I need (Get Therapy Birmingham, 2025 ).

    This is the moral defence: the internalisation of guilt as a protection against the even more terrifying experience of helplessness and abandonment. As Fairbairn understood, it is a form of guilt that serves a psychological function — it preserves a fantasy of control in a situation of genuine powerlessness. But its cost is devastating. The child — and later the adult — carries a pervasive, diffuse sense of being fundamentally at fault, fundamentally unworthy, fundamentally responsible for every relational rupture they encounter (Carveth, n.d.).

    Schizoid Guilt Versus Depressive Guilt: A Crucial Distinction

    One of the most important and frequently misunderstood distinctions in the psychoanalytic literature concerns the fundamental difference between schizoid guilt and depressive guilt. Fairbairn was explicit: the schizoid individual’s central difficulty is not guilt in the mature, object-relational sense, but rather the terror of destroying the other through the force of their own need and love. The depressive individual, by contrast, is primarily troubled by guilt — by the fear that their aggression and hatred have damaged the beloved object (Christiansen, 2025).

    The psychoanalytic theorist Donald Carveth has argued with particular clarity that what presents as guilt in schizoid individuals is more precisely described as unconscious self-punishment — a narcissistic, persecutory phenomenon rooted in the paranoid-schizoid position rather than the authentic, object-oriented concern for the other that characterises mature depressive guilt. Authentic guilt, as Winnicott described it through his concept of the capacity for concern, moves the person toward the other — toward repair and reparation. Schizoid self-torment moves the person inward, into a closed circuit of suffering that intensifies isolation rather than motivating connection (Carveth, n.d.).

    The Closed System and the Inner Prison

    Fairbairn described the schizoid personality as operating within a closed system — a psychological structure in which internal object relationships are maintained in rigorous isolation from the external world and from new relational experience (Integrative Therapy, n.d.). This closed system quality has profound implications for schizoid guilt. Ordinary guilt, in a psychologically healthy individual, can be discharged through a relationship: through acknowledgement, apology, reparation, and the receipt of forgiveness from another person.

    Schizoid guilt, imprisoned within the closed system, has no such discharge pathway. It accumulates without resolution, circulates without outlet, and deepens without relief — not because the schizoid individual is incapable of remorse, but because the relational channels through which guilt is normally processed are defended against with the full force of the schizoid withdrawal (Gerson, 2022).

    Harry Guntrip, who extended Fairbairn’s work through his concept of the withdrawn libidinal ego, described this dynamic with characteristic acuity: the deepest part of the schizoid self — the part that most needs and most fears relationship — has retreated so far into the inner world that it cannot be reached by ordinary relational contact. The guilt it carries is therefore experienced in isolation, without witness, without absolution, and without end (Orcutt, 2018).

    Clinical Presentation: How Schizoid Guilt Appears in Practice

    In clinical settings, schizoid guilt rarely presents as straightforward self-accusation. More commonly, it manifests as a pervasive, low-grade sense of unworthiness, a compulsive tendency toward self-effacement and self-denial, an inability to receive care or positive regard without profound discomfort, and a chronic sense of being somehow defective or fraudulent in social and professional contexts (Salters-Pedneault, 2024). The individual may appear outwardly composed, socially capable, and even intellectually sophisticated — what Guntrip called the “secret schizoid” — while internally experiencing an unremitting sense of badness that they cannot articulate and cannot resolve (ResearchGate, 2024).

    Research on guilt in psychopathology confirms that the distinction between adaptive and maladaptive guilt — between concern-oriented guilt that motivates repair and persecutory self-punitive guilt that maintains suffering — is of direct clinical relevance to treatment planning and outcome (Tilghman-Osborne et al., 2014). The physiological correlates of guilt further confirm its deeply embodied character: guilt activates visceral, physical experiences that can become somatised in individuals who lack the psychological vocabulary to name what they feel (Shields et al., 2023).

    Treatment and the Path Toward Resolution

    The clinical treatment of schizoid guilt is among the most delicate and demanding tasks in psychotherapeutic work, precisely because the relational channel through which resolution must ultimately be achieved is the very channel that the schizoid defences are most committed to protecting. Object relations approaches, rooted in the tradition of Fairbairn, Guntrip, and Winnicott, recommend a therapeutic stance of sustained, non-intrusive presence — offering the patient a relational experience that does not demand emotional reciprocity before it has been earned through trust, and that gently challenges the moral defence without dismantling it prematurely (Get Therapy Birmingham, 2025 ).

    The goal, in Fairbairnian terms, is to open the closed system — to create sufficient conditions of safety for the withdrawn inner self to risk contact with the outer world, and to allow the guilt carried since childhood to be examined, contextualised, and ultimately set down. The object relations literature is consistent in its hopefulness: the schizoid state, for all its fortress-like appearance, conceals not indifference but a profound and enduring hunger for connection — and where that hunger exists, the possibility of healing does too (Orcutt, 2018).

    Conclusion

    Schizoid guilt is one of the most clinically significant and least publicly discussed dimensions of psychological suffering. It is a guilt not born of wrongdoing but of the deeply human response to inadequate love — a guilt that turns the child’s unbearable sense of abandonment into a story they can control, at the cost of carrying that story, silently and alone, into adulthood. Understanding it requires engaging with the richest traditions in psychoanalytic thought, from Fairbairn’s moral defence to Guntrip’s withdrawn self to Winnicott’s capacity for concern. And responding to it — clinically, relationally, or personally — requires precisely what the schizoid defences most resist and most need: a genuine, patient, and ultimately trustworthy encounter with another human being.

    If you are struggling with persistent guilt, self-punishment, or emotional withdrawal and would like to explore therapeutic support, please speak to your GP or a qualified psychotherapist. In the UK, you can also contact the BACP therapist directory at bacp.co.uk or Mind on 0300 123 3393. If you are outside the UK, please contact your local mental health centre.

    References

    Carveth, D. (n.d.) The Unconscious Need for Punishment. York University. Available at: http://www.yorku.ca/dcarveth/guilt.html (Accessed: 20 June 2026).

    Christiansen, N.J. (2025) ‘Melanie Klein’s Notes on Some Schizoid Mechanisms’, Medium. Available at: https://medium.com/@noahjchristiansen/melanie-kleins-notes-on-some-schizoid-mechanisms-c73bf3d18a49 (Accessed: 20 June 2026).

    Gerson, G. (2022) ‘Fairbairn, Winnicott, and Guntrip on the social significance of schizoids’, History of the Human Sciences, 35(3–4), pp. 144–167. Available at: https://journals.sagepub.com/doi/abs/10.1177/09526951211008078 (Accessed: 20 June 2026).

    Gerson, G. (2025) ‘Critical theory and schizoid patients: A look at Winnicott’, Psychoanalysis, Culture & Society. Springer Nature. Available at: https://link.springer.com/article/10.1057/s41282-025-00550-z (Accessed: 20 June 2026).

    Get Therapy Birmingham (2025) The Object Relations Theory of Ronald Fairbairn. Available at: https://gettherapybirmingham.com/post-freudian-psychoanalysis-ronald-fairbairn/ (Accessed: 20 June 2026).

    Integrative Therapy (n.d.) ‘Working with the Defenses of the Withdrawn Child Ego State. Available at: https://integrativetherapy.com/en/articles.php?id=44 (Accessed: 20 June 2026).

    Orcutt, C. (2018) ‘The schizoid analysts who brought relationship to psychoanalysis’, Clio’s Psyche, 24(2), pp. 149–153. Available at: https://cliospsyche.org/articles/orcutt-c-2018-the-schizoid-analysts-who-brought-relationship-to-psychoanalysis-clios-psyche-242-149-153 (Accessed: 20 June 2026).

    ResearchGate (2024) Schizoid Shame: The Idealization of Absence. Available at: https://www.researchgate.net/publication/348261308_Schizoid_Shame_The_Idealization_of_Absence (Accessed: 20 June 2026).

    Salters-Pedneault, K. (2024) ‘Schizoid Personality Disorder’, StatPearls, National Library of Medicine. Available at: https://www.ncbi.nlm.nih.gov/sites/books/NBK559234/ (Accessed: 20 June 2026).

    ScienceDirect (2024) Schizoid Personality Disorder – an overview. Available at: https://www.sciencedirect.com/topics/psychology/schizoid-personality-disorder (Accessed: 20 June 2026).

    Shields, G.S., Durocher, J.J., Fiscus, V.C. and Ford, B.Q. (2023) ‘The psychophysiology of guilt in healthy adults’, Scientific Reports, 13, 13513. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10400478/ (Accessed: 20 June 2026).

    Tilghman-Osborne, C., Cole, D.A. and Felton, J.W. (2014) ‘Definition and measurement of guilt: Implications for clinical research and practice’, Clinical Psychology Review, 30(5), pp. 536–546. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4119878/ (Accessed: 20 June 2026).

  • Trigeminal Neuralgia in the Long-Term: Bidirectional Impact on Psychological Health

    Trigeminal Neuralgia in the Long-Term: Bidirectional Impact on Psychological Health

    Trigeminal Neuralgia (TN) is a rare but devastating neuropathic condition characterised by sudden, electric shock-like episodes of excruciating facial pain distributed along the branches of the trigeminal nerve — the fifth cranial nerve, responsible for sensation across the face. The attacks are frequently triggered by the most mundane of stimuli: brushing teeth, speaking, eating, or even the touch of a gentle breeze. The severity of pain has long been described as among the most intense that human physiology is capable of producing, earning TN its well-known and historically significant designation as the “suicide disease” (Neto et al., 2025 ).

    While this label has been challenged in recent years as medical and surgical treatments have advanced, its existence is not without clinical basis. The psychological burden imposed by long-term TN is substantial, multidimensional, and — critically — profoundly underestimated within mainstream healthcare. This article examines how trigeminal neuralgia influences psychological changes over time, exploring the bidirectional relationship between chronic pain and mental health, the specific psychiatric conditions associated with TN, the risk of suicidality, the disruption to social and occupational functioning, and what the evidence recommends for integrated clinical management.

    Advertisements

    A Bidirectional Relationship: Pain and Mental Health

    The relationship between trigeminal neuralgia and psychological disorders is not unidirectional. Traditionally, the assumption has been that the pain of TN causes secondary mood changes such as depression and anxiety — a logical and intuitive proposition. However, emerging research using Mendelian randomisation analysis — a methodology that applies genetic markers to establish causal direction — has demonstrated that the relationship is in fact bidirectional: not only does TN precipitate psychiatric illness, but pre-existing mental health conditions including depression, anxiety, and insomnia also significantly increase the risk of developing TN in the first instance (Wang et al., 2025).

    A landmark 2025 study published in The Journal of Headache and Pain found that people with depression were more than twice as likely to develop TN, while insomnia and anxiety also significantly elevated TN onset risk. Conversely, carrying a diagnosis of TN increased the risk of developing anxiety by 43%, depression by 30%, and insomnia by nearly 40% (TNA, 2025). Furthermore, the study confirmed that longer disease duration and broader trigeminal nerve involvement were independently associated with increased severity of depressive, anxiety, and insomnia symptoms — underscoring a dose-response relationship between the chronicity of TN and the depth of its psychological toll (Wang et al., 2025).

    Depression: The Most Prevalent Psychological Consequence

    Depression is the most consistently documented psychological comorbidity in TN populations and one of the most clinically consequential. The mechanism is well-evidenced: chronic, unrelenting pain of the intensity characteristic of TN depletes neurochemical resources, disrupts sleep architecture, undermines the capacity for daily functioning, and progressively narrows the individual’s world — all known aetiological contributors to major depressive disorder (Wu et al., 2019). The unpredictability of TN attacks — which can occur without warning at any moment during waking hours — generates a state of sustained psychological vigilance that, over time, mirrors the cognitive and physiological features of a depressive episode.

    A systematic review published in Neurosurgery Reviews in 2025 — the first of its kind to comprehensively examine the psychological burden of TN — confirmed that TN patients carry significantly elevated rates of depressive disorders across multiple validated assessment tools, including the PHQ-9, Hamilton Depression Rating Scale, and Hospital Anxiety and Depression Scale. Critically, the review also found that surgical treatments, particularly microvascular decompression (MVD), effectively alleviated both pain and depressive symptoms, while multidisciplinary approaches combining psychological support with neurorehabilitation yielded the best overall outcomes — a finding with direct implications for how NHS services structure TN care pathways (Martinelli et al., 2025).

    Anxiety, Anticipatory Fear, and Catastrophising

    Anxiety in TN takes a form that is, in many respects, distinct from generalised anxiety disorder as it presents in the broader population. The central driver is anticipatory fear — the perpetual, hypervigilant dread of the next attack. Because TN pain is triggered by ordinary activities that cannot be permanently avoided — talking, eating, drinking, facial exposure to air — affected individuals frequently develop avoidance behaviours that progressively restrict their lives. They stop eating in public. They cease speaking unnecessarily. They avoid wind, cold, and touch with an intensity that begins to resemble phobic avoidance (Wu et al., 2019).

    Research comparing patients with TN against those with persistent idiopathic facial pain found that anxiety symptoms were significantly more elevated in the TN group, and that for individuals reporting prior trauma exposure, PTSD symptoms were also significantly greater among TN patients than comparison groups (ScienceDirect, 2025). The phenomenon of pain catastrophising — a cognitive pattern in which individuals magnify the threat value of pain, ruminate on its impact, and feel helpless in the face of it — is documented at elevated rates in TN and has been shown to independently worsen both pain perception and psychological outcomes over time (Frontiers in Neurology, 2025).

    PTSD, Trauma, and the Neurological Siege

    The conceptualisation of TN-related suffering within a trauma framework is gaining increasing traction in the clinical literature, and it is not difficult to understand why. The lived experience of TN — sudden, violent, entirely unpredictable episodes of pain that resist personal control and occur in the context of innocuous daily activities — shares structural features with the traumatic experiences that give rise to post-traumatic stress disorder. The nervous system learns to associate ordinary environmental stimuli with overwhelming threat, generating the hyperarousal, intrusive re-experiencing, and avoidance behaviours that characterise PTSD (Neto et al., 2025 ).

    Emerging evidence confirms that PTSD symptoms are measurably elevated in TN populations, particularly in those with longer disease duration, greater pain intensity, and inadequate treatment response. The systematic review by Martinelli et al. noted that sleep disorders — which are independently associated with the development and maintenance of PTSD — were among the most prevalent and underaddressed comorbidities in TN patients, creating a reinforcing cycle of neurological and psychological distress that becomes progressively more difficult to interrupt without targeted intervention (Martinelli et al., 2025).

    Suicidality: An Urgent and Under-Addressed Clinical Concern

    The designation of TN as the “suicide disease” demands honest and careful clinical scrutiny. A 2025 study conducted by researchers from Harvard Medical School and Massachusetts General Hospital — the largest study to date examining suicidality in TN — recruited 229 adults with TN and related conditions between December 2023 and January 2024. Their findings were sobering: suicidal ideation was found at clinically significant rates within the sample, and was strongly associated with high pain intensity, elevated anxiety, and severe depression (Fishbein, Bakhshaie and Greenberg, 2025). The authors concluded that suicidality is an urgent yet substantially under-addressed concern among adults with TN, and that its association with pain intensity places comprehensive psychological screening at the centre of responsible clinical management.

    Research examining psychological status in TN patients before and after surgical intervention has further identified that the risk of suicidal ideation is significantly higher in patients with atypical TN (TN2) than in those with classical TN (TN1), requiring more intensive psychological monitoring in this subgroup — and supporting the argument that indications for surgical treatment should be established with urgency in patients at elevated psychological risk (ScienceDirect, 2021). While the “suicide disease” label may now be contextually outdated given advances in surgical and pharmacological treatment, it retains clinical utility as a reminder of the severity of psychological risk that chronic, inadequately managed TN produces (Neto et al., 2025 ).

    Social Isolation, Identity, and Occupational Disruption

    Beyond the domain of discrete psychiatric diagnoses, TN exerts a pervasive and devastating influence on social functioning, personal identity, and occupational engagement. The avoidance behaviours generated by anticipatory fear — the withdrawal from eating, speaking, and social interaction — progressively erode the structures around which personal identity is built. Work becomes impossible, or severely constrained, for many individuals during active disease phases. Social relationships deteriorate under the weight of unexplained withdrawal and communicative limitation. For those who depend on speech professionally — teachers, therapists, lawyers, performers — the occupational consequences can be total and permanent (TNA, 2025).

    The psychological literature consistently identifies social isolation as both a consequence and an amplifier of chronic pain, generating a self-reinforcing cycle in which pain produces withdrawal, withdrawal reduces protective social buffering, and the absence of social support intensifies the subjective experience and psychological weight of pain. In TN, where the very act of social communication — speaking — can trigger an attack, this cycle is particularly vicious and particularly difficult to interrupt without targeted psychosocial intervention alongside physical pain management (Frontiers in Neurology, 2025).

    Treatment Implications: The Case for Multidisciplinary Care

    The weight of evidence reviewed here makes a compelling and unambiguous case for the integration of psychological support into the standard clinical management of trigeminal neuralgia. Pharmacological and surgical interventions — carbamazepine and oxcarbazepine as first-line medications, microvascular decompression as the preferred surgical option for suitable candidates — address the neurological substrate of TN pain with variable success, but do not in themselves address the psychological sequelae that accumulate across the duration of the illness (Martinelli et al., 2025).

    The systematic review by Martinelli et al. explicitly concluded that standardising psychological assessment and treatment methodologies is crucial for optimising TN management outcomes — and that multidisciplinary approaches combining psychological support with neurorehabilitation consistently yield superior results to purely biomedical approaches alone. The Trigeminal Neuralgia Association UK has similarly called for psychological therapy, pain counselling, and sleep support to be embedded as standard within TN care pathways — not optional additions, but structural components of responsible clinical provision (TNA, 2025).

    Conclusion

    Trigeminal neuralgia is not merely a condition of the face. It is a condition of the whole person — neurological in origin, but psychological in consequence, social in impact, and existential in the challenges it poses to identity, connection, and the basic quality of human experience. The long-term psychological changes it produces — depression, anxiety, anticipatory fear, PTSD-like trauma responses, suicidal ideation, social withdrawal, and occupational collapse — are not incidental features of living with chronic pain. They are clinical realities that demand clinical responses: structured, evidence-based, and delivered alongside rather than after physical pain management. Recognising TN as the biopsychosocial emergency it truly is remains one of the most important steps the clinical and research communities can take toward meaningfully improving outcomes for those who live with this condition.

    If you or someone you know is living with chronic pain and experiencing thoughts of suicide or self-harm, please contact the Samaritans on 116 123 (free, 24/7 in the UK) or speak to your GP or local NHS mental health service as soon as possible. If you are seeking help from outside the UK, call your local support service.

    References

    Fishbein, N.S., Bakhshaie, J. and Greenberg, J. (2025) ‘Suicidal Ideation and Self-Injury in Trigeminal Neuralgia’, Journal of Pain Research, 18, pp. 2003–2010. Available at: https://www.dovepress.com/suicidal-ideation-and-self-injury-in-trigeminal-neuralgia-peer-reviewed-fulltext-article-JPR (Accessed: 10 June 2026).

    Frontiers in Neurology (2025) ‘Effects of risk factor-based targeted nursing intervention on psychological status, sleep quality, and pain in patients with trigeminal neuralgia’, Frontiers in Neurology. Available at: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1681364/full (Accessed: 10 June 2026).

    Martinelli, R., Vannuccini, S., Burattini, B., D’Alessandris, Q.G., D’Ercole, M., Izzo, A., Chieffo, D.P.R., Doglietto, F. and Montano, N. (2025) ‘Psychological assessment in patients affected by trigeminal neuralgia: a systematic review’, Neurosurgery Reviews, 48(1), 414. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069416/ (Accessed: 10 June 2026).

    Neto, R., Fonseca Silva, B., Remelhe, M. and Araujo, R. (2025) ‘Trigeminal Neuralgia — rethinking the “suicide disease” label’, European Psychiatry. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12438733/ (Accessed: 10 June 2026).

    ScienceDirect (2021) ‘Psychological status before and after surgery in patients with trigeminal neuralgia’, Journal of Clinical Neuroscience. Available at: https://www.sciencedirect.com/science/article/abs/pii/S0303846721001050 (Accessed: 10 June 2026).

    ScienceDirect (2025) ‘Psychological profiles and sleep quality differences between patients with persistent idiopathic facial pain and trigeminal neuralgia: a 7-year retrospective study’, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. Available at: https://www.sciencedirect.com/science/article/abs/pii/S2212440325007746 (Accessed: 10 June 2026).

    Trigeminal Neuralgia Association UK (2025) Trigeminal Neuralgia and Mental Health. Available at: https://www.tna.org.uk/ceo/trigeminal-neuralgia-and-mental-health/ (Accessed: 10 June 2026).

    Wang, J., Li, M., Zhang, Z., Duan, Y., Zhang, Z., Liu, H. et al. (2025) ‘Association between mental disorders and trigeminal neuralgia: a cohort study and Mendelian randomization analysis’, The Journal of Headache and Pain, 26, 74. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11992777/ (Accessed: 10 June 2026).

    Wu, T.H., Hu, L.Y., Lu, T. et al. (2019) ‘Effects of Depression and Anxiety on Microvascular Decompression Outcome for Trigeminal Neuralgia Patients’, World Neurosurgery. Available at: https://www.sciencedirect.com/science/article/abs/pii/S1878875019311891 (Accessed: 10 June 2026).

  • Allostatic Load and the “Pace of Life Syndrome” in Borderline Personality Disorder: What the Evidence Tells Us

    Allostatic Load and the “Pace of Life Syndrome” in Borderline Personality Disorder: What the Evidence Tells Us

    Borderline Personality Disorder (BPD) is widely understood as a condition of profound emotional and psychological instability — a disorder that disrupts relationships, identity, and the capacity for self-regulation. What is far less widely appreciated, however, is the degree to which BPD is also a disorder of the body. Beneath the clinical surface of emotional dysregulation lies a measurable, multi-system biological crisis rooted in chronic stress exposure, early adversity, and accelerated physiological deterioration. Two theoretical frameworks are increasingly central to understanding this phenomenon: the concept of Allostatic Load (AL) and the evolutionary model known as the Pace-of-Life Syndrome (PoLS). Together, these frameworks offer a powerful lens through which to understand why individuals with BPD experience dramatically shortened lifespans and elevated rates of physical illness — and why addressing these realities must become a clinical and policy priority in the United Kingdom.

    Advertisements

    Understanding Allostatic Load

    The concept of allostatic load was originally developed by the American neuroscientist Bruce McEwen in 1998 to quantify the cumulative physiological “wear and tear” that chronic stress inflicts upon the body’s regulatory systems over time. Where acute stress activates adaptive physiological responses — the well-documented fight-or-flight mechanism — chronic stress, when sustained and unresolved, produces a progressive overactivation of those same systems, eventually leading to their dysregulation and breakdown (O’Connor et al., 2020 ). Allostatic load is an objective, composite measure of this accumulated physiological burden, estimated through biomarkers spanning the neuroendocrine, cardiovascular, metabolic, and inflammatory systems — including cortisol, blood pressure, body mass index, C-reactive protein (CRP), and glycated haemoglobin (Jakubowski et al., 2023).

    A large 2025 study drawing on data from 205,504 adults in the UK Biobank — one of the world’s most comprehensive biological research databases — found that elevated allostatic load was associated with a graded increase in cardiovascular disease risk, with neutrophil-driven inflammation emerging as a key biological mediator between chronic stress and cardiac damage (The Mighty, 2025). A further UK Biobank study, using data from the Edinburgh-based Lothian Birth Cohort, demonstrated a significant positive association between allostatic load and accelerated brain ageing — specifically in white matter microstructure — suggesting that chronic stress does not merely age the body, but measurably alters the biological trajectory of the brain itself (Vail et al., 2024).

    The Pace-of-Life Syndrome: BPD as an Evolutionary Adaptation Gone Wrong

    The Pace-of-Life Syndrome is a theoretical model drawn from evolutionary life history theory — a framework that describes how organisms allocate biological resources between survival, growth, and reproduction in response to environmental conditions. In environments characterised by high adversity, unpredictability, and early threat exposure, organisms — including humans — adopt a “fast” life history strategy: accelerating development, reproduction, and metabolic expenditure in response to the implicit biological signal that the future is uncertain and time is short (Otto, Kokkelink and Brüne, 2021). This fast PoLS profile is characterised by heightened impulsivity, earlier reproductive investment, elevated aggression, chronic stress reactivity, and — crucially — a willingness to prioritise short-term gain at the expense of long-term biological maintenance and repair.

    The proposition that BPD reflects a pathological expression of a fast Pace-of-Life Syndrome has been empirically tested and supported. In a controlled study recruiting 95 women, 44 of whom carried a BPD diagnosis, researchers found that BPD patients demonstrated significantly higher scores on fast PoLS indicators: greater childhood adversity, more severe chronic stress, heightened aggressiveness, and — critically — elevated allostatic load compared to controls. The causal pathway revealed was striking: childhood trauma predicted PoLS, which in turn directly predicted allostatic load, providing the first direct empirical evidence of a pathway linking early adversity to somatic deterioration in BPD through the mediating mechanism of life history strategy (Otto, Kokkelink and Brüne, 2021). Put simply, the same psychological adaptations that helped individuals survive early environments of danger and instability are, in adulthood, slowly destroying the body from within.

    💎 The HPA Axis, Childhood Trauma, and BPD

    🧁 Subscribe or Buy a Cupcake for Betshy to get access to the full article.

    It’s worth reading…

    Subscribe

    References

    Biological Psychiatry (2024) ‘Association of Allostatic Load With Depression, Anxiety, and Suicide: A Prospective Cohort Study’, Biological Psychiatry. Available at: https://www.biologicalpsychiatryjournal.com/article/S0006-3223(24)01655-X/abstract (Accessed: 5 June 2026).

    Borderline Support UK (2024) NHS and NICE Guidelines for Treatment of BPD. Available at: https://borderlinesupport.org.uk/lesson/nhs-and-nice-guidelines-for-treatment-of-bpd/ (Accessed: 5 June 2026).

    Bozzatello, P., Marin, G., Gabriele, G., Brasso, C., Rocca, P. and Bellino, S. (2024) ‘Metabolic Dysfunctions, Dysregulation of the Autonomic Nervous System, and Echocardiographic Parameters in Borderline Personality Disorder: A Narrative Review’, International Journal of Molecular Sciences, 25(22), 12286. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11594816/ (Accessed: 5 June 2026).

    British Journal of Medical Practitioners (n.d.) ‘A review of NICE guidelines on the management of Borderline Personality Disorder’, British Journal of Medical Practitioners. Available at: https://www.bjmp.org/content/review-nice-guidelines-management-borderline-personality-disorder (Accessed: 5 June 2026).

    Bunea, I.M., Szentágotai-Tătar, A. and Miu, A.C. (2022) ‘Childhood Trauma, the HPA Axis and Psychiatric Illnesses: A Targeted Literature Synthesis’, Frontiers in Psychiatry, 13, 748372. Available at: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.748372/full (Accessed: 5 June 2026).

    Jakubowski, D., Peterson, C.E., Sun, J., Hoskins, K., Rauscher, G.H. and Argos, M. (2023) ‘Association between adverse childhood experiences and later-life allostatic load in UK Biobank female participants’, Women’s Health, 19. Available at: https://journals.sagepub.com/doi/10.1177/17455057231184325 (Accessed: 5 June 2026).

    Leichsenring, F., Fonagy, P., Heim, N., Kernberg, O.F., Leweke, F., Luyten, P., Salzer, S., Spitzer, C. and Steinert, C. (2024) ‘Borderline personality disorder: a comprehensive review of diagnosis and clinical presentation, etiology, treatment, and current controversies’, World Psychiatry, 23(1), pp. 4–25. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10786009/ (Accessed: 5 June 2026).

    National Institute for Health and Care Excellence (2009) Borderline Personality Disorder: Recognition and Management (CG78). Available at: https://www.nice.org.uk/guidance/cg78 (Accessed: 5 June 2026).

    O’Connor, R.C., Wetherall, K., Cleare, S., Eschle-Taylor, S., Bhatt, M. and Kirtley, O.J. (2020) ‘Effects of childhood trauma, daily stress, and emotions on cortisol levels in people at elevated suicide risk’, Journal of Abnormal Psychology. White Rose Universities Consortium. Available at: https://eprints.whiterose.ac.uk/id/eprint/150681/3/OConnor%20et%20al_J_Abn_Psyc_ACCEPTED.pdf (Accessed: 5 June 2026).

    Otto, B., Kokkelink, L. and Brüne, M. (2021) ‘Borderline Personality Disorder in a “Life History Theory” Perspective: Evidence for a Fast “Pace-of-Life-Syndrome”‘, Frontiers in Psychology, 12, 715153. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350476/ (Accessed: 5 June 2026).

    The Mighty (2025) What Is Allostatic Load? The Science of Trauma on the Body. Available at: https://themighty.com/topic/post-traumatic-stress-disorder-ptsd/what-is-allostatic-load/ (Accessed: 5 June 2026).

    Vail, E. et al. (2024) ‘Association between allostatic load and accelerated white matter brain aging: findings from the UK Biobank’, medRxiv [Preprint]. Available at: https://www.medrxiv.org/content/10.1101/2024.01.26.24301793.full.pdf (Accessed: 5 June 2026).

  • Borderline Personality Disorder and Life Expectancy: Examining the Evidence Behind the Premature Death Claim

    Borderline Personality Disorder and Life Expectancy: Examining the Evidence Behind the Premature Death Claim

    Among the many sobering realities associated with Borderline Personality Disorder (BPD), perhaps none demands more urgent clinical and public attention than its profound impact on life expectancy. A claim now circulating widely in mental health discourse — that BPD can shorten a person’s life by up to 20 years — is not a figure born of speculation. It is grounded in a growing body of peer-reviewed longitudinal research that collectively paints a troubling picture of premature mortality risk in this population. Yet the “20-year” headline, while broadly accurate, is more nuanced than it first appears. The evidence points to a range of outcomes shaped by comorbidities, socioeconomic factors, access to care, and biological mechanisms that science is only beginning to fully understand. This article examines that evidence in detail, interrogating where the figure comes from, what drives it, and what can be done to narrow the gap.

    Advertisements

    Where Does the “20-Year” Figure Come From?

    The most frequently cited estimate is that individuals with BPD face a reduction in life expectancy of approximately 10 to 20 years compared to the general population (Euler et al., 2025 ). Other studies extend this further: longitudinal research has estimated that people with personality disturbances more broadly — with BPD representing the most clinically severe — face a reduction in life expectancy of between 13 and 27.5 years, owing to a substantially elevated all-cause mortality risk, particularly among younger individuals (Rincón Ferrari et al., 2024). This wide range reflects genuine variation in study design, sample characteristics, and follow-up periods — but across all estimates, the direction of the evidence is unambiguous: BPD is associated with markedly shortened lifespans.

    The most methodologically rigorous evidence underpinning this claim comes from the McLean Study of Adult Development (MSAD), a prospective 24-year longitudinal investigation conducted at Harvard-affiliated McLean Hospital. Following 290 patients with BPD against 72 comparison patients with other personality disorders, the study found that after 24 years, 5.9% of BPD patients had died by suicide, compared with 1.4% of comparison patients. More strikingly, a further 14.0% of BPD patients died from other causes — nearly three times the 5.5% rate observed in the comparison group (Temes et al., 2019). The principal investigators concluded that premature mortality in BPD is comparable in scale to that observed in other serious mental illnesses, including schizophrenia and treatment-resistant mood disorders (Medscape, 2019).

    Suicide: Real, Significant, But Not the Whole Story

    Any honest discussion of BPD mortality must begin with suicide, which remains the most clinically visible and statistically documented contributor to early death in this population. Between 46% and 92% of individuals with BPD will attempt suicide at least once during their lifetime, and between 3% and 10% will die by suicide — a rate dramatically higher than both the general population and many other psychiatric diagnoses (Euler et al., 2025 ). Factors shown to predict completed suicide in BPD include prior suicidal behaviour, a greater number of psychiatric hospitalisations, and the presence of significant psychiatric comorbidities (Medscape, 2019).

    However, a critical finding from the McLean MSAD and subsequent studies is that suicide alone does not account for the full extent of the mortality gap. In the McLean cohort, non-suicidal causes of death — including cardiovascular disease (n=11), substance-related complications (n=5), cancer (n=4), and accidents (n=4) — collectively exceeded suicide as a cause of premature death in BPD patients who did not achieve recovery (Temes et al., 2019). This finding has significant implications for how clinicians approach the condition: a singular focus on suicide prevention, while essential, is insufficient to address the full spectrum of life-threatening risk.

    Physical Health: The Silent Driver of Early Death

    The physical health burden carried by individuals with BPD is substantially underappreciated in mainstream clinical and public discourse. Research confirms that BPD independently elevates the risk of cardiovascular disease, hypertension, obesity, diabetes, arteriosclerosis, arthritis, gastrointestinal disorders, hepatic disease, and sexually transmitted infections (Rincón Ferrari et al., 2024). A dedicated echocardiographic study found that female BPD patients showed significantly increased epicardial adipose tissue — an established sensitive marker for cardiovascular disease risk — alongside reduced indices of cardiac function, compared to matched controls, suggesting that structural cardiac changes may begin early in the illness course (Euler et al., 2025 ).

    The theoretical framework known as the “Pace-of-Life Syndrome” offers one explanatory model for why physical deterioration occurs so pervasively in BPD. Rooted in evolutionary biology, this framework argues that the chronic stress, early adversity, and emotional hyperreactivity characteristic of BPD produce a state of elevated allostatic load — the cumulative physiological wear caused by chronic psychological stress — that accelerates biological ageing and systemic organ damage over time (Otto, Kokkelink and Brüne, 2021). In clinical settings, BPD is associated with an 8.3-fold higher all-cause mortality compared to the general population — a figure that situates it firmly in the category of serious public health concern (Otto, Kokkelink and Brüne, 2021).

    Comorbidities and the Compounding Effect

    BPD rarely exists in isolation, and the life expectancy implications of its comorbidities are considerable. The vast majority of individuals diagnosed with BPD also experience at least one mood disorder — most commonly major depressive disorder or bipolar disorder — alongside elevated rates of anxiety disorders, post-traumatic stress disorder, eating disorders, and attention-deficit hyperactivity disorder (MH Stats, 2026). Substance Use Disorders (SUD) are present in approximately 60% of clinical BPD samples and constitute one of the strongest independent predictors of non-suicidal premature death, contributing directly to cardiovascular complications, accidental overdose, and immune system compromise over time (Grouport Therapy, 2023).

    The temporal dimension of BPD across the lifespan adds further complexity. Research shows that while core BPD symptoms — including affective dysregulation, impulsivity, and suicidality — tend to diminish in intensity with age, maladaptive interpersonal functioning and functional impairment often persist and evolve in presentation, meaning that risk does not simply disappear as patients grow older (Zanarini et al., 2019). The cumulative toll of decades of emotional dysregulation, poor health behaviours, medication side effects, and systemic neglect by healthcare services produces a form of accelerated biological ageing that is difficult to reverse in later life.

    Stigma, Systemic Barriers, and the Access Gap

    A crucial but frequently overlooked contributor to the mortality gap in BPD is the pervasive stigma attached to the diagnosis — both among the general public and within healthcare systems themselves. Individuals with BPD consistently report experiencing negative, dismissive, or even punitive treatment from health practitioners, which generates significant reluctance to seek medical care and sustain treatment engagement (Euler et al., 2025 ). This stigma compounds the already considerable barriers to accessing consistent, high-quality physical and mental healthcare — particularly in under-resourced healthcare systems where BPD-specific expertise is limited (MH Stats, 2026). A significant treatment delay exists between the onset of BPD symptoms, which often emerge in adolescence, and the point at which an individual first receives an accurate diagnosis and appropriate care (MH Stats, 2026).

    Closing the Gap: What the Evidence Recommends

    The mortality gap associated with BPD is not immutable. Effective interventions exist, and early deployment of these interventions measurably improves both quality of life and long-term survival outcomes. Dialectical Behaviour Therapy (DBT), the gold-standard treatment specifically developed for BPD, has demonstrated robust efficacy in reducing self-harm, suicidality, emotional dysregulation, and the impulsive health-damaging behaviours that drive early physical deterioration (Biology Insights, 2025). Researchers from McLean Hospital have called for treatment models that go beyond symptomatic management to actively address poor health behaviours, substance use, social isolation, and physical health monitoring — paralleling rehabilitation approaches used in schizophrenia care (Medscape, 2019).

    Integrated care models that coordinate psychiatric treatment with primary and physical healthcare are strongly supported by current evidence (Biology Insights, 2025). The scientometric literature on BPD spanning twenty years of published research has also called for greater global investment in BPD-specific clinical trials, standardised treatment protocols, and anti-stigma initiatives at both clinical and policy levels (Liu et al., 2024).

    Conclusion

    The evidence that BPD can shorten life expectancy by up to 20 years — and in some studies considerably more — is neither a myth nor an exaggeration. It is a research-grounded reality that emerges consistently across longitudinal studies, biological investigations, and clinical reviews. Suicide, while a defining risk, is only one contributor within a broader constellation of physical illness, psychiatric comorbidity, substance use, systemic neglect, and chronic biological stress that collectively erodes the lifespans of those living with this diagnosis. What the science now makes clear is that BPD must be treated not merely as a mental health condition, but as a serious, life-limiting illness warranting the same level of coordinated, sustained, and adequately funded clinical attention that other life-shortening disorders receive.

    If you or someone you know is living with BPD or experiencing thoughts of self-harm or suicide, please reach out for support. In the UK, contact NHS 111 (option 2), or the Samaritans on 116 123 (free, 24/7). In the US, call or text 988 (Suicide and Crisis Lifeline). Wherever you are, seek support if you don’t already have it.

    References

    Biology Insights (2025) What Is the Mortality Rate for BPD? Available at: https://biologyinsights.com/what-is-the-mortality-rate-for-bpd/ (Accessed: 1 June 2026).

    Euler, S. et al. (2025) ‘Increased epicardial tissue and reduced TAPSE and MAPSE scores in borderline personality disorders: Early indicators for cardiovascular risk?’, PMC. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12175066/ (Accessed: 1 June 2026).

    Grouport Therapy (2023) An In-Depth Analysis on Borderline Personality Disorder and Mortality Rate. Available at: https://www.grouporttherapy.com/blog/bpd-mortality-rate (Accessed: 1 June 2026).

    Liu, Y. et al. (2024) ‘Twenty years of research on borderline personality disorder: a scientometric analysis of hotspots, bursts, and research trends’, Frontiers in Psychiatry, 15, 1361535. Available at: https://pubmed.ncbi.nlm.nih.gov/38495902/ (Accessed: 1 June 2026).

    Medscape (2019) ‘Early Death in BPD Patients Not Just Because of Suicide’, Medscape, 24 May. Available at: https://www.medscape.com/viewarticle/913222 (Accessed: 1 June 2026).

    MH Stats (2026) Borderline Personality Disorder Statistics 2026. Available at: https://mhstats.org/conditions/bpd/ (Accessed: 1 June 2026).

    Otto, B., Kokkelink, L. and Brüne, M. (2021) ‘Borderline Personality Disorder in a “Life History Theory” Perspective: Evidence for a Fast “Pace-of-Life-Syndrome”‘, Frontiers in Psychology, 12, 715153. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350476/ (Accessed: 1 June 2026).

    Rincón Ferrari, M.D. et al. (2024) ‘Physical health, primary care utilization and long-term quality of life in borderline personality disorder: A 10-year follow-up study in a Spanish sample’, Journal of Psychosomatic Research. Available at: https://www.sciencedirect.com/science/article/abs/pii/S0022399924000357 (Accessed: 1 June 2026).

    Temes, C.M. et al. (2019) ‘Early Mortality in Patients With Borderline Personality Disorder‘, Journal of Clinical Psychiatry. Reported in: Psychiatry Advisor. Available at: https://www.psychiatryadvisor.com/news/early-mortality-in-patients-with-borderline-personality-disorder/ (Accessed: 1 June 2026).

    Zanarini, M.C. et al. (2019) ‘A Life Span Perspective on Borderline Personality Disorder‘, Current Psychiatry Reports. Available at: https://link.springer.com/article/10.1007/s11920-019-1040-1 (Accessed: 1 June 2026).

  • 7 Things Every Person Diagnosed with Schizophrenia Should Know About the Mental Health Act in the UK

    7 Things Every Person Diagnosed with Schizophrenia Should Know About the Mental Health Act in the UK

    For individuals living with schizophrenia in the United Kingdom, understanding the legal framework that governs mental health care is not merely an academic exercise — it is a matter of fundamental rights. The Mental Health Act 1983, as significantly amended by the Mental Health Act 2007 and now further reformed by the Mental Health Act 2025, is the primary piece of legislation that determines when and how a person with a mental disorder can be detained in hospital, treated, and supported in the community (Mental Health Act 2025 ). Schizophrenia is explicitly recognised within this legal framework as a condition that falls under the Act’s definition of mental disorder (South West Yorkshire Partnership NHS Foundation Trust, 2024). Whether you are a patient, a carer, or a family member, this knowledge can make a profound difference at a critical time.

    Advertisements

    It is important to note that the Mental Health Act applies to England and Wales. Separate statutory provisions govern Scotland and Northern Ireland (House of Commons Library, 2024). This article outlines the key things every person with schizophrenia should know about their rights under this legislation.

    1. The Act Applies Directly to Schizophrenia

    The Mental Health Act defines mental disorder as “any disorder or disability of the mind.” This definition is deliberately broad and is widely understood by psychiatrists to include schizophrenia, alongside major depression, bipolar disorder, and other serious mental illnesses (South West Yorkshire Partnership NHS Foundation Trust, 2024). However, having a diagnosis of schizophrenia alone does not automatically mean a person is subject to the Act’s provisions. A person must also pose a risk to themselves or others, and less restrictive alternatives must have already been considered and found insufficient (Northamptonshire Healthcare NHS Foundation Trust, n.d.).

    2. Understanding “Sectioning” — What It Really Means

    Being “sectioned” means being detained in hospital under one of the sections of the Mental Health Act, even if you do not consent. This is done to keep you safe and to ensure you receive necessary treatment (Mind, 2025). The most frequently used sections are Section 2 and Section 3. Section 2 is an assessment order lasting up to 28 days and cannot be renewed; if further hospitalisation is needed, clinicians must move to a Section 3 order. Under the Mental Health Act 2025, the initial Section 3 detention period has been reduced from six months to three months, with more frequent mandatory reviews to ensure detention is only used when necessary (Community Care, 2026). Section 4 is an emergency provision lasting 72 hours, used only when waiting for a second doctor would cause a dangerous delay (Mind, 2025).

    3. You Have the Right to Appeal Your Detention

    One of the most critical rights every detained person with schizophrenia should exercise is the right to appeal. Under Section 2, a patient can apply to the First-Tier Tribunal (Mental Health) within the first 21 days of detention. Under Section 3, this window has been extended under the 2025 reforms, and automatic referrals to the tribunal now occur after three months and then every 12 months — ensuring far more frequent independent reviews than previously required (Royal College of Psychiatrists, 2026). Detained persons have the statutory right to be represented at tribunal hearings by a solicitor (Rethink Mental Illness, 2026). Patients can also appeal directly to the hospital managers, who have the authority to discharge them from detention.

    4. You Are Entitled to an Independent Mental Health Advocate (IMHA)

    Every patient detained under the Mental Health Act has a legal right to access an Independent Mental Health Advocate (IMHA). IMHAs are specially trained advocates who can help patients understand their rights, attend meetings on their behalf, and ensure their voice is heard in care planning decisions (Rethink Mental Illness, 2026). A significant improvement introduced by the Mental Health Act 2025 is the extension of this right to informal (voluntary) patients in England — a right that was previously only available to those formally detained. The Act also introduces an “opt-out” system, meaning hospitals must proactively notify advocacy services of qualifying patients, rather than leaving patients to seek help themselves (Local Government Association, 2025). If you or a loved one with schizophrenia is admitted to hospital, requesting an IMHA should be a priority.

    5. Your Right to Free Aftercare Under Section 117

    Section 117 of the Mental Health Act is one of the most practically important — and most underutilised — legal protections available to people with schizophrenia. If you have been detained under Section 3 (or several other qualifying sections), the NHS and your local authority have a legal duty to provide free aftercare services upon discharge (South London and Maudsley NHS Foundation Trust, n.d.). These aftercare services may include community mental health support, housing assistance, medication management, and social care. These services cannot be charged to the patient. A care plan must be written in advance of discharge, identifying the support to be provided and who is responsible for each element (South London and Maudsley NHS Foundation Trust, n.d.). The Mental Health Act 2025 has further strengthened Section 117 by clarifying which local authority holds responsibility when a patient is placed out of their home area, and by empowering the Mental Health Tribunal to recommend that aftercare be put in place — and to reconvene if those recommendations are ignored (Community Care, 2026).

    6. The Nominated Person — Replacing the “Nearest Relative”

    Previously, the law designated a “nearest relative” for each detained patient — a role determined by a fixed legal hierarchy regardless of the patient’s actual wishes or relationships. The Mental Health Act 2025 replaces this with the concept of a “nominated person” — someone the patient themselves chooses to fulfil this important role (House of Commons Library, 2024). For people with schizophrenia, who may have complex or difficult family dynamics, this change is enormously significant. The nominated person has statutory rights, including the ability to request a patient’s discharge, object to detention, and be consulted on care plans. Choosing a trusted nominated person in advance — ideally in conjunction with an Advance Choice Document — is one of the most empowering steps a person with schizophrenia can take.

    7. The Mental Health Act 2025 — What Has Changed and Why It Matters

    The Mental Health Act 2025 received Royal Assent on 18 December 2025, representing the most significant reform of UK mental health law in over four decades (Royal College of Psychiatrists, 2026). The reforms were driven by several longstanding concerns: rising rates of detention, significant racial inequalities in the use of compulsory powers, and the inappropriate detention of autistic people and those with learning disabilities (Care Quality Commission, 2025). For people with schizophrenia, the core ambition of the new Act — to ensure that detention is only used when, and for as long as, strictly necessary — is directly relevant. The Care Quality Commission, which regulates the Act’s use, has emphasised its commitment to revising the Code of Practice in 2026 to embed principles of choice, autonomy, least restriction, and therapeutic benefit at the heart of clinical decision-making (Care Quality Commission, 2025). Crucially, the Act is expected to be implemented in stages over approximately ten years, meaning some changes will not come into effect immediately.

    Conclusion

    Navigating the mental health system can be deeply challenging for anyone living with schizophrenia, but being informed about your legal rights is an essential first step toward self-advocacy and empowered care. From understanding the difference between Section 2 and Section 3, to accessing an IMHA, claiming your Section 117 aftercare entitlements, and choosing a nominated person, the law provides meaningful protections that every patient, carer, and family member should know. The Mental Health Act 2025 marks a significant step forward in placing the patient’s voice at the centre of care — but realising that promise will require both systemic investment and individual awareness. If you need immediate guidance, charities such as Mind and Rethink Mental Illness provide free, accessible information and support.

    References

    Care Quality Commission (2025) The Mental Health Act 1983 (amended 2025). Available at: https://www.cqc.org.uk/publications/monitoring-mental-health-act/2024-2025/mha (Accessed: 18 May 2026).

    Community Care (2024) ‘How the government plans to reform the Mental Health Act 1983’, Community Care, 7 November. Available at: https://www.communitycare.co.uk/2024/11/07/how-the-government-plans-to-reform-the-mental-health-act-1983/ (Accessed: 18 May 2026).

    Community Care (2026) ‘The Mental Health Act 2025 summarised’, Community Care, 11 March. Available at: https://www.communitycare.co.uk/content/news/the-mental-health-act-2025-summarised (Accessed: 18 May 2026).

    House of Commons Library (2024) Reforming the Mental Health Act: Independent Review to Draft Bill. Available at: https://commonslibrary.parliament.uk/research-briefings/cbp-9132/ (Accessed: 18 May 2026).

    Local Government Association (2025) Get in on the Act: Mental Health Act 2025. Available at: https://www.local.gov.uk/publications/get-act-mental-health-act-2025 (Accessed: 18 May 2026).

    Mental Health Act 2025 (c. 33). Available at: https://www.legislation.gov.uk/ukpga/2025/33/enacted (Accessed: 18 May 2026).

    Mind (2025) Being Sectioned Under the Mental Health Act. Available at: https://www.mind.org.uk/information-support/legal-rights/sectioning/about-sectioning/ (Accessed: 18 May 2026).

    Northamptonshire Healthcare NHS Foundation Trust (n.d.) Mental Health Act. Available at: https://www.nhft.nhs.uk/mental-health-act (Accessed: 18 May 2026).

    Rethink Mental Illness (2026) What is the Mental Health Act? Available at: https://www.rethink.org/advice-and-information/rights-laws-and-criminal-justice/mental-health-laws/mental-health-act/ (Accessed: 18 May 2026).

    Royal College of Psychiatrists (2026) ‘Mental Health Bill (England and Wales) receives Royal Assent’, 14 January. Available at: https://www.rcpsych.ac.uk/news-and-features/latest-news/detail/2026/01/14/mental-health-bill-(england-and-wales)-receives-royal-assent (Accessed: 18 May 2026).

    Royal College of Psychiatrists (n.d.) Reforming the Mental Health Act. Available at: https://www.rcpsych.ac.uk/improving-care/campaigning-for-better-mental-health-policy/reforming-the-mental-health-act (Accessed: 18 May 2026).

    South London and Maudsley NHS Foundation Trust (n.d.) Section 117 Aftercare. Available at: https://slam.nhs.uk/section-117-aftercare (Accessed: 18 May 2026).

    South West Yorkshire Partnership NHS Foundation Trust (2024) Mental Health Act. Available at: https://www.southwestyorkshire.nhs.uk/service-users-and-carers/your-rights/mental-health-act/ (Accessed: 18 May 2026).

  • Chronic Asthenia: Causes, Symptoms, Diagnosis, and Evidence-Based Treatment

    Chronic Asthenia: Causes, Symptoms, Diagnosis, and Evidence-Based Treatment

    Chronic asthenia is a multifaceted clinical syndrome defined by persistent, generalised physical weakness and profound fatigue that endures beyond six months in duration and significantly impairs a patient’s capacity to perform daily activities (Clínica Universidad de Navarra, n.d. ). Unlike ordinary tiredness which typically resolves with adequate rest, chronic asthenia persists even at rest and worsens with even minimal physical or cognitive effort (Quironsalud, n.d.). The condition represents one of the most common and yet frequently misunderstood presentations in general medical practice, carrying substantial implications for quality of life, healthcare utilisation, and socioeconomic productivity.

    Advertisements

    Although often discussed interchangeably with chronic fatigue, asthenia is a distinct clinical entity. In contemporary medical literature, asthenia broadly refers to a subjective sensation of weakness and reduced capacity for physical or mental work, whether or not brought on by exertion (Osmosis, n.d.). This article provides a comprehensive overview of chronic asthenia, encompassing its definitions, aetiology, clinical presentation, diagnostic approaches, and evidence-based treatment strategies.

    Defining Chronic Asthenia

    The term “asthenia” derives from the Greek astheneia, meaning “without strength.” Clinically, it describes generalised weakness or a lack of energy perceived by the patient independently of physical or mental strain (Medical News Today, 2023). When fatigue persists for more than one month, it is characterised as prolonged; when it endures beyond six months and reduces an individual’s functional capacity by more than 50%, it meets the clinical criteria for chronic asthenia which, in some diagnostic frameworks, overlaps significantly with chronic fatigue syndrome (Clí­nica Universidad de Navarra, n.d.).

    The chronic variant is distinguished from transient or acute asthenia not only by its duration but also by its severity and resistance to conventional rest. Patients with chronic asthenia frequently describe an inability to engage meaningfully in occupational, social, or domestic activities, representing a profound reduction in their overall quality of life (Quironsalud, n.d.). It is equally important to differentiate asthenia clinically from dizziness and dyspnoea, conditions with which patients frequently confuse it, given the overlapping nature of their subjective experiences (Roca Fernández et al., 2010).

    Epidemiology and Prevalence

    Chronic asthenia is not a rare complaint. Fatigue and generalised weakness rank among the most common reasons patients seek medical consultation worldwide (Clí­nica Universidad de Navarra, n.d.). Its prevalence is particularly elevated among individuals living with advanced or chronic medical conditions; asthenia has been documented in 60-90% of advanced cancer patients across multiple studies, making it the most prevalent symptom in that population (ScienceDirect, n.d.).

    Beyond oncology, asthenia is a recognised consequence of numerous systemic, neurological, and psychiatric conditions, meaning its true epidemiological footprint across general medicine is likely underestimated. Strikingly, depression alone accounts for approximately half of all cases presenting with significant fatigue or asthenic symptoms, underscoring the imperative for thorough differential diagnosis in clinical settings (Roca Fernández et al., 2010).

    Aetiology and Risk Factors

    Chronic asthenia is not a disease in itself but rather a symptom or syndrome arising from a wide spectrum of underlying conditions (Medical News Today, 2023). Its aetiological profile is broad, encompassing biological, psychological, and pharmacological causes.

    Medical and Systemic Conditions

    Chronic illnesses are among the most common drivers of persistent asthenia. These include diabetes mellitus, anaemia, thyroid dysfunction, particularly hypothyroidism, multiple sclerosis, chronic kidney disease, cardiac failure, and autoimmune conditions (Wellyme.org, 2024). Endocrine disorders such as Addison’s disease, and electrolyte imbalances including hyponatraemia and hypokalaemia, are also recognised reversible causes that clinicians should actively investigate (ScienceDirect, n.d.).

    Surgical interventions can precipitate chronic asthenia. Research has demonstrated that total thyroidectomy is associated with a worsening of chronic asthenia post-operatively, while hemithyroidectomy does not carry the same risk, suggesting a direct relationship between hormonal status and asthenic symptomatology (Paja-Fano et al., 2017). Additionally, age-related muscle loss as seen in sarcopenia contributes to frailty and may manifest as asthenic features in older adults (Cleveland Clinic, 2026).

    Neurological and Cognitive Dimensions

    From a neurological perspective, chronic asthenia is a well-established feature of numerous central nervous system diseases and is deeply intertwined with cognitive dysfunction. Research has shown that asthenia functions initially as a protective physiological signal indicating depletion of energy resources; however, it can progress into a pathological, immune-mediated condition, particularly in its most severe manifestation, chronic fatigue syndrome (Vasenina, Gankina and Levin, 2023). Cognitive deficits in attention, memory, and executive function are frequently co-present with asthenic states, substantially complicating both diagnosis and clinical management (Vasenina, Gankina and Levin, 2023).

    Psychological and Psychiatric Causes

    The psychiatric dimension of chronic asthenia is substantial and must not be overlooked in clinical assessment. As previously noted, depression is the single most frequent identifiable cause, accounting for approximately half of all chronic asthenia presentations (Roca Fernández et al., 2010). Anxiety disorders, chronic psychological stress, and post-traumatic stress disorder have all been implicated in producing perceived weakness through neurochemical imbalances that manifest as physical symptoms (Study.com, 2016). Research into neurocirculatory asthenia found that in approximately 59% of patients, a diagnosable psychiatric condition, most commonly an anxiety disorder, preceded the onset of asthenic symptoms, with these patients demonstrating significantly elevated levels of anxiety, depression, social phobia, and impaired quality of life (Fava et al., 1994).

    Pharmacological Causes

    Certain medications are known to induce asthenia as a side effect. Chemotherapeutic agents, muscle relaxants, antihypertensives, and sedative drugs are among the most frequently implicated pharmacological contributors (Wellyme.org, 2024). In such cases, management may involve adjusting the dosage or substituting an alternative medication, though any such modification must be undertaken strictly under medical supervision (Medical News Today, 2023).

    Clinical Presentation and Symptoms

    The cardinal symptom of chronic asthenia is persistent, intense fatigue that does not improve with rest and significantly impairs the individual’s functional capacity across occupational, social, and personal domains (Clínica Universidad de Navarra, n.d.). Additional symptoms commonly reported include persistent headaches; muscle weakness and pain; disordered sleep; cognitive difficulties colloquially termed “brain fog,” encompassing poor concentration and memory lapses; low-grade fever, particularly in the afternoon; sore throat; swollen cervical lymph nodes; social withdrawal; and emotional dysregulation (Quironsalud, n.d.; Cleveland Clinic, 2026).

    In its most severe form, Grade 4 asthenia, the patient may be entirely bedridden and completely unable to perform any daily activities, typically as a consequence of serious underlying illness or aggressive medical treatments such as chemotherapy (Quironsalud, n.d.). Beyond its physical dimensions, asthenia carries mental and emotional weight that further interferes with the individual’s ability to perform activities of daily living, generating significant negative effects on social functioning and economic participation (Springer Nature, 2015).

    Diagnosis

    The diagnosis of chronic asthenia is primarily clinical and hinges upon the systematic exclusion of other identifiable causes. No single laboratory test or imaging study can confirm the diagnosis; instead, clinicians employ a comprehensive battery of investigations to rule out organic pathology (Clí­nica Universidad de Navarra, n.d.). The diagnostic process must exclude drug dependency, infections, autoimmune and immune disorders, muscular or neurological diseases such as multiple sclerosis, endocrine conditions including hypothyroidism, cardiac and hepatorenal pathology, psychiatric illness, particularly depression and malignancy (Clí­nica Universidad de Navarra, n.d.).

    Despite thorough investigation, up to 20% of patients presenting with chronic asthenic symptoms remain without a definitive aetiological diagnosis, highlighting the complex and incompletely understood nature of the condition (Roca Fernández et al., 2010). Where chronic fatigue syndrome is suspected as the underlying syndrome, the international consensus criteria of 1994 commonly (known as the Fukuda criteria) remain widely applied in clinical practice, though updated frameworks from the Institute of Medicine (2015) have gained increasing international acceptance.

    Treatment and Management

    Given the heterogeneous aetiology of chronic asthenia, its treatment must be personalised and delivered through a multidisciplinary framework.

    Treating the Underlying Cause

    The most effective therapeutic strategy remains the identification and correction of the underlying condition (Osmosis, n.d.). Reversible causes, including anaemia, infection, electrolyte imbalances, and endocrine dysfunction, should be prioritised and treated accordingly (ScienceDirect, n.d.).

    Pharmacological Interventions

    Pharmacological management may include corticosteroids, which can provide short-term relief of asthenic symptoms; however, their benefits generally last only two to four weeks, and long-term use carries significant adverse effects, meaning there is presently no consensus on optimal dosage or regimen (ScienceDirect, n.d.). Iron supplementation is appropriate for anaemic patients, while antimicrobial therapy is indicated when infection serves as the precipitating cause (Wellyme.org, 2024).

    Non-Pharmacological Approaches

    Non-pharmacological interventions are increasingly supported by clinical evidence. Structured exercise programmes have demonstrated measurable improvements in energy levels, muscle function, and overall wellbeing among patients with chronic asthenia and related conditions (ScienceDirect, n.d.). Cognitive behavioural therapy (CBT) has been utilised to address the psychological dimensions of the condition, assisting patients in reframing maladaptive thought patterns, managing emotional responses, and improving functional engagement (Osmosis, n.d.). Acupuncture has similarly demonstrated modest clinical benefit in symptom management in select patient populations (ScienceDirect, n.d.).

    Lifestyle modifications encompassing balanced and nutrient-rich dietary intake, structured sleep hygiene practices, vaccination programmes to reduce infection risk, and stress management techniques such as mindfulness meditation and yoga constitute important adjuncts to formal medical treatment (Wellyme.org, 2024; Cleveland Clinic, 2026).

    Impact on Quality of Life

    The burden of chronic asthenia extends well beyond the individual patient. Research has consistently demonstrated that asthenia exerts significant physical, mental, and emotional impairments that disrupt occupational performance, social relationships, and economic participation, with notable indirect consequences for caregivers and family members (Springer Nature, 2015). In oncology, where asthenia is most prevalent, studies have found that its impact on quality of life endures longer than the effects of pain or depression among patients undergoing chemotherapy, reinforcing the urgent need for proactive and sustained management strategies (Springer Nature, 2015).

    The pathophysiology of asthenia, particularly in chronic and cancer-related forms, remains incompletely understood, and the evidence base supporting established therapeutic strategies is limited, representing a significant gap in current clinical research (ScienceDirect, n.d.).

    Conclusion

    Chronic asthenia is a complex, multidimensional syndrome that demands careful clinical attention and a personalised, evidence-based approach to management. Its capacity to manifest across virtually all medical specialities, from neurology and oncology to psychiatry and endocrinology, makes it both a diagnostic challenge and a significant contributor to patient morbidity. Raising awareness of its diverse clinical presentation, advancing diagnostic precision, and expanding access to integrated, multidisciplinary treatment pathways are essential steps toward improving outcomes for the many individuals living with this profoundly disabling condition. Future research must prioritise the development of validated biomarkers and standardised therapeutic protocols to close the considerable gaps that remain in clinical understanding.

    References

    Cleveland Clinic (2026) Asthenia (Weakness) Causes, Symptoms & Treatment. Available at: https://my.clevelandclinic.org/health/symptoms/asthenia-weakness (Accessed: 15 May 2026).

    Clínica Universidad de Navarra (n.d.) Chronic Fatigue, Chronic Fatigue or Chronic Asthenia. Available at: https://www.cun.es/en/diseases-treatments/diseases/chronic-asthenia (Accessed: 15 May 2026).

    Fava, G.A., Grandi, S., Michelacci, L., Saviotti, F.M., Conti, S. and Bellini, G. (1994) ‘Neurocirculatory asthenia: A reassessment using modern psychosomatic criteria’, Journal of Clinical Psychiatry, 55(12). Available at: https://pubmed.ncbi.nlm.nih.gov/8067269/ (Accessed: 15 May 2026).

    Medical News Today (2023) Asthenia (Weakness): Causes, Symptoms, and Treatment. Available at: https://www.medicalnewstoday.com/articles/asthenia-weakness (Accessed: 15 May 2026).

    Osmosis (n.d.) Asthenia: What Is It, Causes, Symptoms, Diagnosis, and More. Available at: https://www.osmosis.org/answers/asthenia (Accessed: 15 May 2026).

    Paja-Fano, M., Oleaga-Alday, A., Pérez de Nanclares, G., Portillo, P., Gorria, I., Pereda, A. and Zubicaray, J. (2017) ‘The prevalence of post-thyroidectomy chronic asthenia: a prospective cohort study’, Langenbeck’s Archives of Surgery, 402(4), pp. 611- 617. Available at: https://pubmed.ncbi.nlm.nih.gov/28299450/ (Accessed: 15 May 2026).

    Quironsalud (n.d.) Asthenia. Available at: https://www.quironsalud.com/en/diseases-symptoms/asthenia (Accessed: 15 May 2026).

    Roca Fernández, J.J. et al. (2010) ‘The chronic asthenia syndrome: a clinical approach’, PubMed [PMID: 20529781]. Available at: https://pubmed.ncbi.nlm.nih.gov/20529781/ (Accessed: 15 May 2026).

    ScienceDirect (n.d.) Asthenia:an overview. Available at: https://www.sciencedirect.com/topics/medicine-and-dentistry/asthenia (Accessed: 15 May 2026).

    Springer Nature (2015) ‘Asthenia’, in Palliative Medicine and Supportive Care. Cham: Springer International Publishing. Available at: https://link.springer.com/chapter/10.1007/978-3-319-21683-6_38 (Accessed: 15 May 2026).

    Study.com (2016) Asthenia: Definition, Symptoms & Treatment. Available at: https://study.com/academy/lesson/asthenia-definition-symptoms-treatment.html (Accessed: 15 May 2026).

    Vasenina, E.E., Gankina, O.A. and Levin, O.S. (2023) ‘Stress, Asthenia, and Cognitive Disorders’, Neuroscience and Behavioral Physiology, 53(2), pp. 249-255. Available at: https://link.springer.com/article/10.1007/s11055-023-01364-1(Accessed: 15 May 2026).

    Wellyme.org (2024) Asthenia: Causes, Symptoms, Diagnosis, and Treatment. Available at: https://www.wellyme.org/post/asthenia-causes-symptoms-diagnosis-and-treatment (Accessed: 15 May 2026).

  • The Psychological Trauma of Being Arrested: Understanding Its Impact

    The Psychological Trauma of Being Arrested: Understanding Its Impact

    As someone who has worked with trauma survivors and lived through my own mental health challenges, I know how deeply an arrest can wound a person — even when no conviction follows. Being arrested is not just a legal event; it is often a profound psychological trauma that can leave lasting scars on the mind, body, and sense of self.

    Advertisements

    The moment of arrest triggers an immediate and intense activation of the body’s stress response. Handcuffs, physical restraint, public exposure, and the sudden loss of freedom flood the nervous system with cortisol and adrenaline. Many people describe it as feeling like “time stops” or entering a dissociative state. This acute stress can be as traumatic as a physical assault, especially when force is used or the arrest feels unjustified (Geller et al., 2014) .

    For many, the trauma begins with the loss of autonomy. Being placed in handcuffs, searched, and transported in a police vehicle can trigger deep feelings of powerlessness and humiliation. Research shows that individuals who experience arrest often report symptoms similar to those seen in post-traumatic stress disorder (PTSD), including intrusive memories, hypervigilance, nightmares, and avoidance behaviours (Sugie and Turney, 2017). The public nature of many arrests adds a layer of social shame that can persist for years.

    The psychological impact extends far beyond the event itself. Even a short period in custody can shatter a person’s sense of safety and trust in the world. For those with pre-existing trauma, an arrest can re-activate old wounds, leading to complex PTSD symptoms. Many report lasting changes in how they view authority figures, institutions, and even their own worth. The stigma of having been arrested — whether charges are dropped or not — can damage relationships, employment prospects, and self-identity (Baćak and Nowotny, 2020).

    Physiologically, the body remembers. Chronic hyperarousal, sleep disturbances, and heightened startle responses are common. Some individuals develop somatic symptoms such as tension headaches, gastrointestinal issues, or chronic pain as the body continues to hold and convert the unprocessed trauma. Studies on recently arrested individuals show elevated rates of depression, anxiety, and substance use as maladaptive coping mechanisms.

    The trauma is often compounded by systemic factors. Marginalised communities — particularly people of colour, those from low-income backgrounds, and individuals with mental health conditions — experience higher rates of arrest and report more traumatic encounters with law enforcement. This creates a cycle where systemic injustice and personal trauma reinforce each other (Sewell et al., 2021).

    Recovery from arrest-related trauma requires gentle, trauma-informed support. Approaches such as EMDR (Eye Movement Desensitisation and Reprocessing), somatic experiencing, and trauma-focused cognitive behavioural therapy can be highly effective. Equally important is social validation — being believed and supported rather than judged or stigmatised.

    In my forensic journey and personal reflections, I have seen how an arrest can fracture a person’s sense of safety in the world. Healing begins when we acknowledge the depth of that wound without shame. If you or someone you love has experienced the trauma of arrest, know that your reactions are normal responses to an abnormal event. You are not broken — you are responding to something that was profoundly violating.

    The trauma of being arrested reminds us how fragile our sense of freedom and dignity can be. By bringing awareness and compassion to this experience, we take an important step toward healing both individuals and the systems that sometimes cause unnecessary harm.

    References

    Baćak, V. and Nowotny, K. M. (2020) ‘Criminal justice contact and health: Does race matter?’, Sociology of Race and Ethnicity, 6(3), pp. 337–352. Available at: https://journals.sagepub.com/doi/full/10.1177/0038040720914863 (Accessed: 26 March 2026).

    Geller, A. et al. (2014) ‘Aggressive policing and the mental health of young urban men’, American Journal of Public Health, 104(12), pp. 2321–2327. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103812/ (Accessed: 26 March 2026).

    Sewell, A. A. et al. (2021) ‘Police violence and public health: A review of the literature’, Annual Review of Sociology, 47, pp. 527–548. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118190/ (Accessed: 26 March 2026).

    Sugie, N. F. and Turney, K. (2017) ‘Beyond incarceration: Criminal justice contact and mental health’, American Sociological Review, 82(4), pp. 719–743. Available at: https://journals.sagepub.com/doi/full/10.1177/0003122416687318 (Accessed: 26 March 2026).